--- title: "A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Moves" type: "News" locale: "en" url: "https://longbridge.com/en/news/276640284.md" description: "Abbott Laboratories (ABT) is gaining attention as its share price remains flat over the past week but shows a 4.46% gain over the last month. Currently priced at $112.21, it is considered undervalued compared to a fair value of $133.39, indicating a potential intrinsic discount of about 28%. The company's growth is supported by expanding healthcare access in emerging markets, although risks such as tariffs and pricing pressures could impact future performance. Investors are encouraged to explore additional opportunities in undervalued stocks and resilient companies." datetime: "2026-02-23T20:16:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276640284.md) - [en](https://longbridge.com/en/news/276640284.md) - [zh-HK](https://longbridge.com/zh-HK/news/276640284.md) --- # A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Moves ## Why Abbott Laboratories (ABT) is Back on Investors’ Radar Abbott Laboratories (ABT) is drawing fresh attention after recent share price moves, with the stock roughly flat over the past week but showing a gain over the past month and weaker returns over the past year. See our latest analysis for Abbott Laboratories. At a share price of US$112.21, Abbott’s recent 4.46% 1 month share price return contrasts with its weaker year to date share price performance and a 15.27% 1 year total shareholder return. This suggests earlier enthusiasm has cooled rather than accelerated. If Abbott’s recent moves have you reassessing healthcare exposure, it could be a good moment to widen your watchlist with our screener of 27 healthcare AI stocks as potential next ideas to research. With Abbott trading at US$112.21, some metrics, including an indicated intrinsic discount of about 28%, hint at potential value still on the table. This raises the question: is this a genuine opening, or is the market already pricing in future growth? ## Most Popular Narrative: 15.9% Undervalued At a last close of $112.21 versus a narrative fair value of about $133.39, the most followed view sees Abbott as trading below its estimated worth, built on detailed forecasts for revenue, margins and future valuation multiples discounted at 7.79%. > _The expansion of healthcare access and rising middle class in key emerging markets (such as India, China, Latin America, and the Middle East) is fueling robust growth in branded generics and biosimilars, highlighted by Abbott's record sales in these regions and imminent biosimilar launches, this trend is poised to drive sustained double-digit top-line growth and greater geographic revenue diversification._ _Read the complete narrative._ Read the complete narrative. Want to see what sits behind that fair value gap? The narrative leans heavily on multi year revenue growth, shifting profit margins and a richer future earnings multiple. The exact mix of these ingredients may surprise you. **Result: Fair Value of $133.39 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on diagnostics and diabetes devices holding up. Ongoing tariffs, currency swings and pricing pressure in key markets could quickly challenge that thesis. Find out about the key risks to this Abbott Laboratories narrative. ## Next Steps Curious whether the optimism or the caution should matter more for you right now? Take a moment to review the key figures, weigh the trade offs, and see how 4 key rewards and 1 important warning sign shapes your own conclusion. ## Ready to hunt for your next idea? If you stop with just one stock today, you could miss other opportunities that fit your goals even better, so broaden your search before you decide. - Target potential bargains with our list of 53 high quality undervalued stocks that pair stronger fundamentals with prices that may not fully reflect them yet. - Prioritize resilience by checking out 85 resilient stocks with low risk scores, built around companies with lower risk scores that may better suit a steadier approach. - Seek out tomorrow’s standouts early by reviewing our screener containing 23 high quality undiscovered gems, where quality metrics highlight ideas the market might not be focused on yet. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [ABT.US](https://longbridge.com/en/quote/ABT.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [ABL.US](https://longbridge.com/en/quote/ABL.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [XHE.US](https://longbridge.com/en/quote/XHE.US.md) ## Related News & Research - [Vise Technologies Inc. Grows Holdings in Abbott Laboratories $ABT](https://longbridge.com/en/news/288930165.md) - [Rep. Rick W. Allen Sells Abbott Laboratories (NYSE:ABT) Stock](https://longbridge.com/en/news/289187025.md) - [New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis | ABT Stock News](https://longbridge.com/en/news/288932412.md) - [Abbott Labs must face lawsuit over PediaSure children's growth claims](https://longbridge.com/en/news/288764700.md) - [Wells Fargo Reaffirms Their Buy Rating on Abbott Laboratories (ABT)](https://longbridge.com/en/news/285317649.md)